Last reviewed · How we verify
NCT07310186
Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy
trial testing observational study in Diffuse Large B Cell Lymphoma (DLBCL) in 200 participants. Not yet recruiting.
30 December 2026
Quick facts
| Lead sponsor | Peking Union Medical College Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 200 |
| Start date | 30 December 2025 |
| Primary completion | 30 December 2026 |
| Estimated completion | 30 December 2027 |
Drugs / interventions tested
- observational study — full drug profile →
Conditions studied
- Diffuse Large B Cell Lymphoma (DLBCL) — all drugs for Diffuse Large B Cell Lymphoma (DLBCL) →
Sponsor
Peking Union Medical College Hospital
Who can join
18 and older, any sex, with Diffuse Large B Cell Lymphoma (DLBCL). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Diffuse Large B-cell Lymphoma (DLBCL) is a common hematologic malignancy. Even after standard first-line treatment, approximately 40% of patients will experience relapse. Currently, polatuzumab vedotin (pola) has been incorporated into DLBCL treatment (both for newly diagnosed and relapsed cases). However, for patients whose disease progresses after pola-containing regimens, the subsequent treatment options, efficacy, and survival outcomes remain unclear. Understanding these real-world scenarios is of great significance, as it can guide clinicians in developing better and more tailored treatment strategies for patients in the future. Therefore, we plan to conduct this real-world study titled "Salvage Treatment Strategies and Clinical Outcomes in Diffuse Large B-cell Lymphoma After Failure of Polatuzumab Vedotin-based Combination Therapy", aiming to obtain real-world data from the Chinese population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07310186
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational study
Trials testing the same drug.
- NCT07497139 — Sepsis Induced Myocardial Injury in Critically Ill Children · not yet recruiting
- NCT07379567 — BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED · not yet recruiting
- NCT07391007 — Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases · not yet recruiting
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT07306325 — Ultrasound in Predicting Difficult Intubation in Acromegaly Patients · not yet recruiting
Other recruiting trials for Diffuse Large B Cell Lymphoma (DLBCL)
Currently open trials in the same condition.
- NCT07523737 — Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Dif · Phase 2 · recruiting
- NCT07371923 — Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell Lymphoma · Phase 2 · recruiting
- NCT07062627 — Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma · Phase 2 · recruiting
- NCT07260812 — KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · Phase 1 · recruiting
- NCT07124936 — A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma · Phase 1, PHASE2 · recruiting
Other Peking Union Medical College Hospital trials
Trials by the same sponsor.
- NCT07466251 — PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke · Phase 4 · not yet recruiting
- NCT06743321 — Speech-to-speech Voice-cloning Care (SVCC) to Improve ICU-acquired Anxiety for Critically Ill Patients · NA · not yet recruiting
- NCT07590336 — 68Ga-NYM207 PET/CT Imaging in Hepatocellular Carcinoma · Phase 1, PHASE2 · not yet recruiting
- NCT07515976 — Mapping of Genomic Structural Variations in Major Birth Defects · not yet recruiting
- NCT07386756 — Early Precise Identification and Intervention Strategies for Individuals at High Risk of Prediabetes · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07310186 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Peking Union Medical College Hospital
- Last refreshed: 30 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07310186.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing